A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

Unlocking the potential of antibody–drug conjugates for cancer therapy

(2021) Joshua Z. Drago et al.   Nature Reviews Clinical Oncology

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates

(2021) Julien Dugal-Tessier et al.   Journal of Clinical Medicine

Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

(2021) Aleksandr V. Yurkovetskiy et al.   MOLECULAR CANCER THERAPEUTICS

Advances and Limitations of Antibody Drug Conjugates for Cancer

(2021) Candice Maria Mckertish et al.   Biomedicines

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy

(2021) Juliana T. W. Tong et al.   MOLECULES

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond

(2021) Charalampos Theocharopoulos et al.   Vaccines

Trastuzumab Deruxtecan: First Approval

(2020) Susan J. Keam   DRUGS

Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

(2020) David M. Goldenberg et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

(2019) Thomas H. Pillow et al.   ChemMedChem

Investigational Antibody–Drug Conjugates for Treatment of B-lineage Malignancies

(2018) Alex F. Herrera et al.   Clinical Lymphoma Myeloma & Leukemia

Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation

(2018) Elena Cini et al.   Chemical Science

Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice

(2018) Yasuaki Anami et al.   Nature Communications

Structural investigation of human S. aureus-targeting antibodies that bind wall teichoic acid

(2018) Rina Fong et al.   mAbs

Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

(2017) Joanna C. Masters et al.   INVESTIGATIONAL NEW DRUGS

Extension of in vivo half-life of biologically active molecules by XTEN protein polymers

(2016) Vladimir N. Podust et al.   JOURNAL OF CONTROLLED RELEASE

Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates

(2016) Jeffrey C. Kern et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

(2016) M. Dorywalska et al.   MOLECULAR CANCER THERAPEUTICS

Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates

(2015) Magdalena Dorywalska et al.   BIOCONJUGATE CHEMISTRY

Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity

(2015) Adam J. R. Gadd et al.   BIOCONJUGATE CHEMISTRY

A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

(2015) A. V. Yurkovetskiy et al.   CANCER RESEARCH

Novel antibody–antibiotic conjugate eliminates intracellular S. aureus

(2015) Sophie M. Lehar et al.   NATURE

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading

(2015) Pavel Strop et al.   NATURE BIOTECHNOLOGY

Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility

(2014) Sheng Ding et al.   BIOCONJUGATE CHEMISTRY

Statistical Modeling of the Drug Load Distribution on Trastuzumab Emtansine (Kadcyla), a Lysine-Linked Antibody Drug Conjugate

(2014) Michael T. Kim et al.   BIOCONJUGATE CHEMISTRY

Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer

(2013) V. N. Podust et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Novel Staphylococcal Glycosyltransferases SdgA and SdgB Mediate Immunogenicity and Protection of Virulence-Associated Cell Wall Proteins

(2013) Wouter L. W. Hazenbos et al.   PLoS Pathogens

Disulfide bond structures of IgG molecules

(2012) Hongcheng Liu et al.   mAbs

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

(2010) A G Polson et al.   LEUKEMIA

Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection

(2009) A. G. Polson et al.   CANCER RESEARCH

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

(2009) Volker Schellenberger et al.   NATURE BIOTECHNOLOGY

Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates

(2008) Stephen C. Alley et al.   BIOCONJUGATE CHEMISTRY

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY